secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0000950170-24-089301
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance
-----------------------------------------------------------------------

- Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).
- Net loss $46.2M vs $47.8M YoY; Adjusted EBITDA loss $21.4M vs $24.8M.
- clonoSEQ test volume 18,520 (+36% YoY); recognized $3.0M MRD regulatory milestone.
- FY 2024 MRD revenue guidance raised to $140-145M (from $135-140M); total OPEX guidance lowered to $340-350M.
- Cash and securities $291.9M as of June 30.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/0000950170-24-089301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000095017024089301/adpt-20240801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-089301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer